Clinical

Dataset Information

0

AntiCEA M3-I


ABSTRACT: Interventions: The trial will involve 20 adult patients with colorectal cancer, to be divided into 2 10-member groups for each dose level. One single intravenous dose of 0.3 or 1mg of fragment marked with 5-7 mCi of 131I will be administered, depending on the group.;Antibodies, Monoclonal;Radioimmunodetection;Iodine Radioisotopes;Injections, Intramuscular;131I-antiCEA M3 Primary outcome(s): Pharmaceutical safety, measuring time: 6 months. Study Design: Allocation: Non-randomized controlled trial. Masking: Open. Control group: Uncontrolled. Assignment: Other. Purpose: Diagnostic

DISEASE(S): Gastrointestinal Diseases,Gastrointestinal Neoplasms,Rectal Diseases,Intestinal Diseases,Colorectal Cancer,Digestive System Diseases,Colorectal Neoplasms,Intestinal Neoplasms,Digestive System Neoplasms,Colonic Diseases

PROVIDER: 2571384 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| PRJNA103125 | ENA
2013-04-15 | GSE41483 | GEO
2023-06-30 | GSE213928 | GEO
2010-11-04 | GSE25144 | GEO
2007-11-01 | GSE9401 | GEO
2023-02-04 | GSE224052 | GEO
2010-11-04 | E-GEOD-25144 | biostudies-arrayexpress
| 2195703 | ecrin-mdr-crc
2013-04-15 | E-GEOD-41483 | biostudies-arrayexpress
2021-12-09 | GSE190509 | GEO